CORDIS
EU research results

CORDIS

English EN

Glaucoma – Advanced, LAbel-free High resolution Automated OCT Diagnostics

Project information

Grant agreement ID: 732613

Status

Closed project

  • Start date

    1 December 2016

  • End date

    30 November 2019

Funded under:

H2020-EU.2.1.1.

  • Overall budget:

    € 3 996 783,75

  • EU contribution

    € 3 996 780

Coordinated by:

Gooch & Housego (Torquay) Limited

United Kingdom

Objective

The project GALAHAD targets the critical need for better glaucoma diagnostic systems. Glaucoma is an age-related major cause of blindness. The eye disease is characterized by an irreversible damage to the optic nerve head caused by increased intra-ocular pressure. The current screening and basic diagnostics for the disease involve intra-ocular pressure measurement, visual field tests and detection of structural damage to the optic nerve head and retinal nerve fibre layer. The present methods have high rates of false positive or false negative results since the in depth analysis of optical nerve head damage is not possible due to the poor resolution of available optical technologies. A leading candidate is optical coherence tomography (OCT), but the required axial resolution is ~1 μm, well beyond the 3-5 μm resolution of commercial systems. GALAHAD aims to develop a label free, compact and easy to operate high resolution diagnostic OCT system. The multiband and multimodal system will use submicron ultra-high resolution polarisation sensitive OCT (UHR PS OCT). The key breakthrough elements are: (i) A revolutionary low cost multiband supercontinuum light source. (ii.) Ground-breaking ultra-broadband photonic components required to exploit such a source. (iii.) Automated glaucoma screening algorithms: using end user evaluation of cell and animal models and tissue samples, automated algorithms will be developed, trained and tested so that non-expert operators will be able to perform glaucoma screening. The GALAHAD in depth glaucoma diagnostics after a positive screening with conventional methods will dramatically reduce false positive and false negative screening results and decrease the number of patients suffering from glaucoma-related disability. The project is driven by world leading companies and manufacturers of OCT systems and guided by requirement specifications and validated by high ranking clinical and experimental ophthalmologists in their clinical settings.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

Gooch & Housego (Torquay) Limited

Address

Broomhill Way Unit A
Tq2 7ql Torquay Devon

United Kingdom

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 779 156

Participants (9)

OPTOS PUBLIC LIMITED COMPANY

United Kingdom

EU Contribution

€ 490 227

NKT PHOTONICS A/S

Denmark

EU Contribution

€ 543 793

IBSEN PHOTONICS AS

Denmark

EU Contribution

€ 480 240

VIVID COMPONENTS LTD

United Kingdom

EU Contribution

€ 214 487

DANMARKS TEKNISKE UNIVERSITET

Denmark

EU Contribution

€ 317 002

UNIVERSITAT POLITECNICA DE VALENCIA

Spain

EU Contribution

€ 329 390

GLOUCESTERSHIRE HOSPITALS NHS FOUNDATION TRUST

United Kingdom

EU Contribution

€ 129 580

WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER

Germany

EU Contribution

€ 473 246

REGION HOVEDSTADEN

Denmark

EU Contribution

€ 239 659

Project information

Grant agreement ID: 732613

Status

Closed project

  • Start date

    1 December 2016

  • End date

    30 November 2019

Funded under:

H2020-EU.2.1.1.

  • Overall budget:

    € 3 996 783,75

  • EU contribution

    € 3 996 780

Coordinated by:

Gooch & Housego (Torquay) Limited

United Kingdom